Strategic considerations for innovation and commercialization in the US biotechnology sector

European Planning Studies

Volumn 15, Issue 6, 2007, Pages 753-766

  Bagchi Sen, Sharmistha ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; COMMERCIALIZATION; FIRM SIZE; INNOVATION; MARKETING; PRODUCT DEVELOPMENT; STRATEGIC APPROACH;

NORTH AMERICA; UNITED STATES;

EID: 34548535665     PISSN: 09654313     EISSN: 14695944     Source Type: Journal    
DOI: 10.1080/09654310701214226     Document Type: Article

References (33)

1. Audretsch, D. (2001) The role of small firms in US biotechnology clusters. Small Business Economics, 17, pp. 3-15.
2. Audretsch, D. and Stephan, P. (1996) Company-scientist locational links: The case of biotechnology. American Economic Review, 86, pp. 641-653.
3. Audretsch, D. and Stephan, P. (1999) Knowledge spillovers in biotechnology: Sources and incentives. Journal of Evolutionary Economics, 9, pp. 97-107.
4. Bagchi-Sen, S., Smith, H. Lawton and Hall, L. (2004) The US biotechnology industry: Industry dynamics and policy. Environment and Planning C, 22, pp. 199-216.
5. Burrill, G. S. (2006) A changing prescription for biotechnology. Paper presented at BIO 2006. Chicago, IL
6. Casper, S. and Karamanos, A. (2003) Commercializing science in Europe: The Cambridge biotechnology cluster. European Planning Studies, 11, pp. 805-822.
7. Cooke, P. (2003) The evolution of biotechnology in three continents: Schumpeterian or Penrosian?. European Planning Studies, 11, pp. 757-763.
8. Cooke, P. (2004) The molecular biotechnology revolution and the rise of bioscience megacentres in North America and Europe. Environment and Planning C, 22, pp. 199-216.
9. Coombs, J. and Deeds, D. (2000) International alliances as sources of capital: Evidence from the biotechnology industry. Journal of High Technology and Management Research, 11, pp. 235-253.
10. Deeds, D. L. and Hill, C. W. L. (1996) Strategic alliances and the rate of new product development: An empirical study of entrepreneurial biotechnology firms. Journal of Business Venturing, 11, pp. 41-55.
11. Feldman, M. P. and Kelley, M. R. (2002) How states augment the capabilities of technology-pioneering firms. Growth and Change, 33, pp. 173-195.
12. Feldman, M. P. and Ronzio, C. R. (2001) Closing the innovative loop: Moving from the laboratory to the shop floor in biotechnology manufacturing. Entrepreneurship and Regional Development, 13, pp. 1-16.
13. Gray, M. (2002) The micro-level matters. Zeitschrift fur Wirtschaftsgeographie, 46, pp. 124-136.
14. Hagedoorn, J., Link, A. and Vonortas, N. (2000) Research partnerships. Research Policy, 29, pp. 567-586.
15. Kenney, M. (1998) Biotechnology and the creation of a new economic space. Private Science: Biotechnology and the Rise of the Molecular Sciences, University of Pennsylvania Press, Philadelphia, PA
16. Lerner, J., Shane, H. and Tsai, A. (2003) Do equity financial cycles matter? Evidence from biotechnology alliances. Journal of Financial Economics, 67, pp. 411-446.
17. Liebeskind, J. P., Oliver, A. L., Zucker, L. G. and Brewer, M. B. (1995) Social Networks, Learning and Flexibility: Sourcing Scientific Knowledge in New Biotechnology Firms, National Bureau of Economic Research, Cambridge, MA
18. Madhok, A. and Osegowitsch, T. (2000) The international biotechnology industry: Dynamic capabilities perspective. Journal of International Business Studies, 31, pp. 325-336.
19. McCutchen Jr, W. W. and Swamidass, P. M. (1998) Explaining the differences in domestic and cross-boundary strategic alliances in the pharmaceutical/biotech industry. International Journal of Technology Management, 15, pp. 490-506.
20. McCutchen Jr, W. W. and Swamidass, P. M. (2004) Motivations for strategic alliances in the pharmaceutical/biotech industry: Some new findings. The Journal of High Technology Management Research, 15, pp. 197-214.
21. Pharmaceutical Research and Manufacturers of America (PhRMA) (2006) Pharmaceutical Industry Profile 2006, PhRMA, Washington, DC
22. Palmintera, D. (2005) Accelerating Economic Development through University Technology Transfer, Innovation Associates Inc, Reston, VA
23. Pisano, G. (1990) The R&D boundaries of the firm: An empirical analysis. Administrative Sciences Quarterly, 35, pp. 153-176.
24. Pisano, G. (1991) The governance of innovation: Vertical integration and collaborative arrangements in the biotechnology industry. Research Policy, 20, pp. 237-249.
25. Powell, W. W. (1998) Learning from collaboration: Knowledge and networks in the biotechnology and pharmaceutical industries. California Management Review, 40, pp. 228-240.
26. Powell, W. W., Koput, K. W., Bowie, J. I. and Smith-Doerr, L. (2002) The spatial clustering of science and capital: Accounting for biotech firm-venture capital relationships. Regional Studies, 36, pp. 291-306.
27. Prevezer, M. (1997) The dynamics of industrial clustering in biotechnology. Small Business Economics, 9, pp. 255-271.
28. Prevezer, M. (2001) Ingredients in the early development of the US biotechnology industry. Small Business Economics, 17, pp. 17-29.
29. Rothaermel, F. (2001) Complimentary assets, strategic alliances, and the incumbent's advantage: An empirical study of industry and firm effects in the biopharmaceutical industry. Research Policy, 30, pp. 1235-1251.
30. Shan, W. and Song, J. (1997) Foreign direct investment and the sourcing of technological advantage: Evidence from the biotechnology industry. Journal of International Business Studies, 28, pp. 267-284.
31. Zeller, C. (2004) North Atlantic innovative relations of Swiss pharmaceuticals and the proximities with regional biotech arenas. Economic Geography, 80, pp. 83-111.
32. Zucker, L. G. and Darby, M. R. (1996) Star Scientists, Institutions, and the Entry of Japanese Biotechnology Enterprises, National Bureau of Economic Research, Cambridge, MA
33. Zucker, L. G., Darby, M. R. and Brewer, M. B. (1998) Intellectual human capital and the birth of US biotechnology enterprises. The American Economic Review, 88, pp. 291-306.